Recorded Webinar | Humira®/Biosimilars Forecast for 2023 and Beyond
You are leaving bbrown.com.
By accessing this link, you will be leaving Brown & Brown’s website and entering a site hosted by another party. Please be advised that you will no longer be subject to the privacy and security policies of Brown & Brown’s website. We encourage you to read and evaluate the privacy and security policies of the site you are entering, which may be different than those of Brown & Brown.
The biosimilars for the blockbuster drug Humira will hit the market in 2023. Watch our team as we discuss the complexities surrounding biosimilars, how they may influence the pharmacy landscape and the important considerations employers should know.